| Authors: |
Wiltzsch V; Department Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany., Dias DB; Julius Wolff Institute, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany., Schmidt JR; Department Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany; Fraunhofer Cluster of Excellence Immune-Mediated Diseases (CIMD), Leipzig, Germany., Kirwan JA; Berlin Institute of Health at Charité -BIH Metabolomics, 10117, Berlin, Germany; University of Veterinary Medicine, Vienna, 1210, Vienna, Austria., Lehmann J; Department Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany; Fraunhofer Cluster of Excellence Immune-Mediated Diseases (CIMD), Leipzig, Germany., Poh PSP; Julius Wolff Institute, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany., Kalkhof S; Department Preclinical Development and Validation, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany; Fraunhofer Cluster of Excellence Immune-Mediated Diseases (CIMD), Leipzig, Germany; Institute for Bioanalysis, University of Applied Science Coburg, Coburg, Germany. Electronic address: stefan.kalkhof@izi.fraunhofer.de. |
